This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Top 10 Buy-Rated Stocks Under $5

8. Achillion Pharmaceuticals (ACHN) shares spiked last month after the company said Phase 1b clinical trial data showed its ACH-1625 treatment in third and fourth patient cohorts achieved "meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C." The stock is down more than 11% over the last month, but has nearly doubled in price over the last year.

Consensus: Of the analysts covering Achillion, seven, or 77.8%, recommend purchasing its shares and two recommend holding them.

Closing Price: $2.33 (June 2)

Bullish Case: Roth Capital Partners has a buy rating and $12 price target on Achillion, which calls for quite a bit of upside based on current levels. "Achillion's strong clinical performance with ACH-1625 to-date, we believe should be of strong interest to investors looking to be involved in the Hepatitis C virus (HCV) space. We believe the drug's profile to-date make it a very attractive partnering candidate," the firm wrote in a research note late last month.

Bearish Scenario: JMP Securities, which has a market perform rating on Achillion, argues that while the company's protease inhibitor looks good so far and suggests potential for once daily dosing, more safety data is needed. "Given how crowded the HCV protease inhibitor class is, combined with the move toward oral combination therapy, we think safety is what will ultimately differentiate these compounds," the firm said.

3 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
RFMD $16.59 -2.07%
ARIA $9.24 0.00%
C $54.17 0.00%
FCEL $1.22 0.00%
MHR $1.98 0.00%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs